4th Pediatric Infectious Diseases Conference
 
 
Home  Back   ISSN 0973 - 0958
 
User name :
Password :
NEONATAL LUPUS SYNDROME
5TH NATIONAL CONFERENCE OF PEDIATRIC RHEUMATOLOGY, KOLKATA, 29TH & 30TH SEPTEMBER 2007

Tapas Sabui
Associate Professor
Pediatrics, NRS Medical College
Kolkata


Madhumita Nandi
Clinical Tutor
IPGMER, Kolkata


The Neonatal Lupus Syndrome (NLS), while quite rare, carry significant mortality and morbidity. Although it is classically believed that the disease is due to transplacental passage of maternal antinuclear antibodies, they are not sufficient to directly cause cardiac scarring. It seems genetic factors are likely to have role in clinical expression. Mothers with HLA DR3 are at increased risk of delivering babies with NLS. Clinical manifestations occur usually within the first 2 months of life. It is characterized by presence of anti SSA/Ro and SSB and/or U1 RNP antibody both in baby and mother. Target organs are heart, skin, liver, blood and gastro-intestinal tract. All clinical manifestations are usually transient except cardiac complications. Cardiac manifestations include complete (classical) or incomplete heart block (CHB) in a structurally normal heart, immune myocarditis, dilated cardiomyopathy and endomyocardial fibroelastosis. Only 2% of fetuses born to mothers with maternal SLE/Connective tissue disorder develop CHB and majority of mothers are usually asymptomatic. The recurrence rate of CHB in subsequent pregnancies is 19%. Once CHB/NLS is suspected in a fetus, echocardiography should be done weekly from 16 to 26 weeks and every other week until about 34 weeks. Until recently, in utero detection of first degree block was not technically feasible. However, the EKG equivalent of the PR interval can now be measured by echocardiography (Mechanical PR). Intervention at this stage with glucocorticoids may decrease acute inflammation but not necessarily prevent subsequent fibrosis.

50% of patients suffer from dermatological complications. Skin lesions are photosensitive and characterized classically by annular erythematous scaling plaques. It frequently involves the face and scalp with characteristic predilection for upper eyelids. Rash is rarely present at birth. Hematological manifestations include thrombocytopenia, immune hemolytic anemia and neutropenia. Incidence of hepatobiliary disease is 19%. Three common clinical presentations are severe hepatic failure, conjugated hyperbilirubinemia with mild or no rise of aminotransferases and asymptomatic mild rise of aminotransferases levels.

Risk factors for death are fetal diagnosis, the presence of hydrops, gestational age under 33 weeks or the development of endocardial fibroelastosis (EFE) with ejection fraction 40%. Outcome is directly related to heart rate and inversely proportional to it. Heart rate 50 is associated with 50% mortality and all survivors require permanent pacing. Heart rate 60 is associated with a mortality of 6% and 20% of survivors require cardiac pacing. EFE occurs despite adequate cardiac pacing and is associated with significant mortality, whether developing in fetal or postnatal life.

Last Updated on 15-12-2007

How to cite this url
5th National Conference of Pediatric Rheumatology - Conference Abstracts. Pediatric Oncall [serial online] 2007 [cited 15 December 2007(Supplement 12)];4. Available from:
http://www.pediatriconcall.com/fordoctor/Conference_abstracts/ncpr/
neonatal_lupus_syndrome.asp
 
 
 
Pedi Poll
Today's Poll
Should teicoplannin, colistin be used in case of neonatal sepsis where culture does not reveal any organism_?
No, it should be used only after drug sensitivity report
Yes, under guidance of an infectious disease expert
Educational Section
 
Disclaimer:
The information given by www.pediatriconcall.com is provided by medical and paramedical & Health providers voluntarily for display & is meant only for informational purpose. The site does not guarantee the accuracy or authenticity of the information. Use of any information is solely at the user's own risk. The appearance of advertisement or product information in the various section in the website does not constitute an endorsement or approval by Pediatric Oncall of the quality or value of the said product or of claims made by its manufacturer.
 
copyright ©2011 website design & development by Levioza
Follow Us
Follow us on :
Folllow Us